A Szarewski, W A J Poppe, S R Skinner, C M Wheeler, J Paavonen, P Naud, J Salmeron, S-N Chow, D Apter, H Kitchener, X Castellsagué, J C Teixeira, J Hedrick, U Jaisamrarn, G Limson, S Garland, B Romanowski, F Y Aoki, T F Schwarz, F X Bosch, D M Harper, K Hardt, T Zahaf, D Descamps, F Struyf, M Lehtinen, G Dubin
In the Phase III PATRICIA study (NCT00122681), the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine (Cervarix(®), GlaxoSmithKline Biologicals) was highly efficacious against HPV-16/18 infections and precancerous lesions in women HPV-16/18 deoxyribose nucleic acid (DNA) negative and seronegative at baseline. We present further data on vaccine efficacy (VE) against HPV-16/18 in the total vaccinated cohort including women who may have been exposed to HPV-16/18 infection before vaccination. In women with no evidence of current or previous HPV-16/18 infection (DNA negative and seronegative), VE was 90...
July 1, 2012: International Journal of Cancer. Journal International du Cancer